These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38520334)

  • 1. Detection of Single Nucleotide Polymorphisms of Circulating Tumor DNA by Strand Displacement Amplification Coupled with Liquid Chromatography.
    Ma Z; Xu J; Hou W; Lei Z; Li T; Shen W; Yu H; Liu C; Zhang J; Tang S
    Anal Chem; 2024 Apr; 96(13):5195-5204. PubMed ID: 38520334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations.
    Poole JC; Wu SF; Lu TT; Vibat CRT; Pham A; Samuelsz E; Patel M; Chen J; Daher T; Singh VM; Arnold LJ
    PLoS One; 2019; 14(10):e0223112. PubMed ID: 31581267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
    Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrimination of the
    Dekaliuk M; Qiu X; Troalen F; Busson P; Hildebrandt N
    ACS Sens; 2019 Oct; 4(10):2786-2793. PubMed ID: 31577130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
    Cho MS; Park CH; Lee S; Park HS
    PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients.
    Tran LS; Pham HT; Tran VU; Tran TT; Dang AH; Le DT; Nguyen SL; Nguyen NV; Nguyen TV; Vo BT; Dao HT; Nguyen NH; Tran TH; Nguyen CV; Pham PC; Dang-Mai AT; Dinh-Nguyen TK; Phan VH; Do TT; Truong Dinh K; Do HN; Phan MD; Giang H; Nguyen HN
    PLoS One; 2019; 14(12):e0226193. PubMed ID: 31841547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex Detection of Single Nucleotide Polymorphisms by Liquid Chromatography for Nonsmall Cell Lung Cancer Staging.
    Song C; Ma Z; Zhang M; Liu C; Tang S; Zhang J; Song J; Yu H; Lee HK; Shen W
    Anal Chem; 2024 Jan; 96(3):1054-1063. PubMed ID: 38190445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.
    Solassol J; Vendrell JA; Senal R; Audran P; Leenhardt F; Quantin X
    Lung Cancer; 2019 Jul; 133():45-47. PubMed ID: 31200827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium.
    van der Leest P; Rozendal P; Hinrichs J; van Noesel CJM; Zwaenepoel K; Deiman B; Huijsmans CJJ; van Eijk R; Speel EJM; van Haastert RJ; Ligtenberg MJL; van Schaik RHN; Jansen MPHM; Dubbink HJ; de Leng WW; Leers MPG; Tamminga M; van den Broek D; van Kempen LC; Schuuring E
    Clin Chem; 2024 May; 70(5):759-767. PubMed ID: 38484302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
    Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
    Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
    Sclafani F; Chau I; Cunningham D; Hahne JC; Vlachogiannis G; Eltahir Z; Lampis A; Braconi C; Kalaitzaki E; De Castro DG; Wotherspoon A; Capdevila J; Glimelius B; Tarazona N; Begum R; Lote H; Hulkki Wilson S; Mentrasti G; Brown G; Tait D; Oates J; Valeri N
    Sci Rep; 2018 Jan; 8(1):1445. PubMed ID: 29362371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
    Chow YP; Zainul Abidin N; Kow KS; Tho LM; Wong CL
    PLoS One; 2022; 17(10):e0276161. PubMed ID: 36256645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
    Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
    Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
    O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
    Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.